• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

Sera Prognostics

edit

Sera Prognostics is a private biotechnology company developing diagnostic tests that use proprietary biomarkers that are predictive of preterm birth and other pregnancy complications. Sera was founded in 2008 and licensed its serum proteomics discovery technology and novel peptides from Brigham Young University and the University of Utah. The company has assembled a board of directors and management team with significant clinical development and women’s healthcare diagnostic experience for translating scientific innovation into commercial products that help patients and build significant corporate value. Sera is located in Salt Lake City, Utah.

Milestones

edit

• 
  Sera Prognostics added Mark J. Ostrowski as President & COO.
  Posted 11/15/11 at 6:16pm
• 
  Sera Prognostics added Gregory C. Critchfield as Chairman and CEO.
  Posted 11/15/11 at 6:16pm
• 
  Sera Prognostics added Andrew A. Sauter as CFO.
  Posted 1/4/11 at 7:32pm
• 
  Sera Prognostics added Kenneth G. Chahine as President & COO.
  Posted 1/4/11 at 7:32pm
• 
  Sera Prognostics added Dennis B. Farrar as Board of Directors.
  Posted 1/4/11 at 7:32pm
• 
  Sera Prognostics received $19.3M in Series A funding. (11/15/11)
  Posted 11/15/11 at 6:13pm via seraprognostics.com
• 
  Sera Prognostics received $1.4M in Series A funding. (1/4/11)
  Posted 1/4/11 at 7:32pm via seraprognostics.com

Videos

Screenshots

edit

Sources

1. Sera Prognostics Closes $1.4 million Series A-­1 Financing (seraprognostics.com) [edit]
2. Sera Secures $19.3 million Financing; Appoints Greg C. Critchfield, MD as Chief Executive Officer (seraprognostics.com) [edit]